<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 22-year-old female with history of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) was referred for evaluation of <z:hpo ids='HP_0000505'>decreased visual acuity</z:hpo> in her right eye </plain></SENT>
<SENT sid="1" pm="."><plain>Her best-corrected visual acuity (BCVA) at the time of presentation was 20/160 </plain></SENT>
<SENT sid="2" pm="."><plain>Widespread <z:e sem="disease" ids="C0271053" disease_type="Disease or Syndrome" abbrv="">cotton wool spots</z:e> and macular <z:hpo ids='HP_0000969'>edema</z:hpo> were seen on biomicroscopy </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="31624">Fluorescein</z:chebi> angiography (FA) revealed <z:chebi fb="46" ids="15035">retinal</z:chebi> arterial and venous obstruction with capillary nonperfusion at the superotemporal retina </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) was diagnosed based on positive <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> anti-coagulant and ocular manifestations </plain></SENT>
<SENT sid="5" pm="."><plain>Scattered laser photocoagulation was applied at the nonperfusion area but the visual acuity continued to deteriorate due to macular <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Intravitreal bevacizumab (<z:mp ids='MP_0010560'>IVB</z:mp>) was administered for macular <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>One day after <z:mp ids='MP_0010560'>IVB</z:mp>, the BCVA decreased to count fingers </plain></SENT>
<SENT sid="8" pm="."><plain>FA revealed extended non-perfusion from the superotemporal area to the posterior pole </plain></SENT>
<SENT sid="9" pm="."><plain>Use of intravitreal bevacizumab for macular <z:hpo ids='HP_0000969'>edema</z:hpo> secondary to SLE or APS should be considered carefully and patients monitored closely for vascular complications </plain></SENT>
</text></document>